Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 61Stomach Neoplasms 46Colorectal Neoplasms 24Esophageal Squamous Cell Carcinoma 19Rectal Neoplasms 11Esophageal Neoplasms 11Pancreatic Neoplasms 7Cholangiocarcinoma 6Liver Neoplasms 5Colonic Neoplasms 4Neoplasms 3Colorectal Cancer Metastatic 3Spinocerebellar Degenerations 2Neoplasm Metastasis 2Locally Advanced Rectal Cancer 2Liver Diseases 2Gastric Adenocarcinoma 2Advanced Biliary Tract Cancer 2Uterine Cervical Neoplasms 1Unresectable Locally Advanced Pancreatic Cancer 1Turcot syndrome 1Tislelizumab 1Small Cell Lung Carcinoma 1Recurrence 1Pancreatic Cancer Resectable 1Pancreatic Cancer Metastatic 1PD-1 Antibody 1Ovarian Neoplasms 1Neoplasms, Squamous Cell 1Microsatellite Stable Metastatic Colorectal Cancer 1

Interventions

Gemcitabine 4130-nm albumin-bound paclitaxel 2sintilimab 1nimotuzumab 1avelumab 1Taxes 1Oxaliplatin 1Leucovorin 1Irinotecan 1Hydroxychloroquine 1Fluorouracil 1Capecitabine 1Antineoplastic Agents 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Cancer Resectable × sintilimab × Gastrointestinal × Clear all
NCT06888674 2025-03-21

Personalized Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer.

Zhejiang University

Phase 1/2 Not yet recruiting
60 enrolled
Gastrointestinal

Pancreatic Cancer Resectable

Data powered by HemOnc (CC BY 4.0) Colophon âš¡